Latest News

Friday, February 27, 2015 | Clinical Trials, Alcon

Phase 2 Data Highlights Benefits of Alcon's RTH258 for Patients with Wet AMD

Alcon presented results from its second phase 2 clinical study of RTH258 during the 38th Annual Macula Society Meeting in Scottsdale, Arizona. The study evaluated the efficacy and safety of the compou…

Read the full story

Friday, February 27, 2015 | Acquisitions/Mergers, Optos

Nikon to Acquire Optos for $400 Million in Cash

Nikon Corp. has agreed to acquire retinal imaging firm Optos for $400 million (259.3 million pounds) in cash, the companies announced Friday. Under terms of the agreement, Nikon will pay 340 pence a s…

Read the full story

Friday, February 27, 2015 | Earnings & Financials

Ocata Therapeutics Approved for Listing on NASDAQ

Ocata Therapeutics, a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, announced that it has received notice that the NASDAQ Listing Qualifications Department h…

Read the full story

Friday, February 27, 2015 | Retina, Regeneron Pharmaceuticals

Eylea Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion

Regeneron Pharmaceuticals announced that Eylea (aflibercept) injection has been approved by the European Commission for the treatment of visual impairment due to macular edema secondary to retinal vei…

Read the full story

Friday, February 27, 2015 | Medical Studies

New Diagnostic Test Proposed for Myasthenia Gravis

Ocular vestibular-evoked myogenic potentials could be the basis of a new test for myasthenia gravis, according to the results of a recent study. "We're very excited because it's a simple …

Read the full story

Friday, February 27, 2015 | Medical Studies

Generic Drug Use Shown to Improve Medication Adherence in People with Glaucoma

In the first study to examine the impact of a reduction in glaucoma medication copay on patient adherence, researchers in Michigan have found a potential solution to one of the biggest obstacles facin…

Read the full story

Thursday, February 26, 2015 | FDA Approval/Clearance

Lupin Receives FDA Approval for Generic Lumigan Ophthalmic Solution 0.03%

Pharma Major Lupin Limited (Lupin) announced that it has received final approval for its bimatoprost ophthalmic solution, 0.03% from the FDA to market a generic version of Allergan's Lumigan Ophth…

Read the full story

Thursday, February 26, 2015 | Product Releases, Carl Zeiss Meditec

Zeiss Launches Humphrey Field Analyzer 3 Visual Field Testing System

At the American Glaucoma Society 2015 annual meeting in Coronado, California, Zeiss is announcing the global launch of the Humphrey Field Analyzer 3 (HFA3), the next generation in visual field t…

Read the full story

Thursday, February 26, 2015 | Miscellaneous

Envision Receives $300K Mabee Challenge Grant for Research Institute

Envision announced that it has received a $300,000 challenge grant from the Tulsa, Oklahoma-based J.E. and L.E. Mabee Foundation, which will support renovation of an entire floor of Envision’s W…

Read the full story

Thursday, February 26, 2015 | Glaucoma

XEN Gel Stent Receives Approval from Health Canada to Treat Glaucoma

AqueSys, the developer of minimally invasive stent technology for the treatment of glaucoma, announced that the company received a Class 3 Medical Device License for the XEN Gel Stent from Health Cana…

Read the full story

Thursday, February 26, 2015 | Medical Studies

New Diagnostic Test Proposed for Myasthenia Gravis

Ocular vestibular-evoked myogenic potentials could be the basis of a new test for myasthenia gravis, according to the results of a recent study. "We're very excited because it's a simple …

Read the full story

Thursday, February 26, 2015 | Medical Studies

New Pathways Discovered to Prevent Blindness

Scientists have made a major new discovery detailing how areas of the brain responsible for vision could potentially adapt to injury or trauma and ultimately prevent blindness. The Monash University l…

Read the full story

Thursday, February 26, 2015 | Medical Studies

Telescopic Contact Lens Shows Promise for AMD

An innovation that combines a telescopic contact lens with "smart" glasses that look like normal eyewear looks set to be a great help to people with serious vision problems, such as age-rela…

Read the full story

Wednesday, February 25, 2015 | Avedro

FDA Advisory Panel Recommends Approval of Avedro’s Cross-Linking Platform

A joint FDA advisory panel on Tuesday recommended approval of Avedro’s combined riboflavin ophthalmic solutions and ultraviolet light irradiation for corneal collagen cross-linking. The recommen…

Read the full story

Wednesday, February 25, 2015 | Medical Studies

Pupil Contraction Test Detects Neuropathy in a Single Eye

Transient pupil contractions in response to bright blue light can objectively reveal optic neuropathy in one eye, independent of its fellow eye, researchers say. "This could be a clinical tool fo…

Read the full story
Load More
 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $28.12  -1.71% 
 Akorn, Inc. $53.81  0.64% 
 Alimera Sciences, Inc. $5.23  -0.95% 
 Allergan, Inc. $232.74  0.15% 
 Avalanche $36.18  -1.55% 
 Bayer $147.73  0.26% 
 Can-Fite Biopharma $4.50  -3.64% 
 Carl Zeiss Meditec $24.57  0.06% 
 Cooper Companies, Inc. $163.97  -0.89% 
 Escalon Medical Corp. $1.45  0.00% 
 Essilor International $116.50  1.30% 
 Imprimis Pharmaceuticals, Inc. $7.50  -3.47% 
 InSite Vision, Inc. $0.19  -7.07% 
 IRIDEX Corporation $10.65  -0.65% 
 Johnson & Johnson $102.51  -0.28% 
 LCA-Vision Inc. $5.37  0.00% 
 Luxottica Group, S.p.A. $61.24  -0.68% 
 Merck & Company, Inc. $58.54  -0.71% 
 NicOx $2.12  1.15% 
 NovaBay Pharmaceuticals, Inc. $0.54  3.85% 
 Novartis AG Common Stock $102.40  -0.58% 
 Ocular Therapeutix $35.77  2.03% 
 Ophthotech Corporation $53.74  -1.94% 
 Quantel $3.46  -1.98% 
 Regeneron $413.84  -1.44% 
 Roche $34.13  0.80% 
 STAAR Surgical Company $6.86  -13.49% 
 TearLab Corporation $2.60  -2.99% 
 Thrombogenics $8.48  0.00% 
 Topcon Corporation $19.85  0.00% 
 Valeant Pharmaceuticals $197.48  -1.87% 
 Xoma $3.69  -3.66%